Business
Investor presentation
Investor presentation.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 0471X Evgen Pharma PLC 17 December 2019 \n\nEvgen Pharma plc\n(\"Evgen Pharma\" or \"the Company\")\n \nInvestor presentation\n \nEvgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it will hold an investor briefing on Tuesday, 14 January 2020. \n \nThe event will take place in the Copper Bar, upstairs at Balls Brothers, 6 Adams Court, Old Broad St, London EC2N 1DX at 4.30pm for a 4.45pm start. This will be followed by drinks and canapés, and a chance to network. Dr Stephen Franklin, CEO and Richard Moulson CFO, will provide a presentation on the Half Year Report including an overview of the Company's strategy.\n \nIf you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].\n \nEnquiries: \n \n\n\n\nEvgen Pharma plc www.evgen.com \n\n\nvia Walbrook\n\n\n\n\nDr Stephen Franklin, CEO \n\n\n\n\n\n\n\nRichard Moulson, CFO \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nfinnCap www.finncap.com \n\n\n+44 (0) 20 7220 0500\n\n\n\n\nGeoff Nash / Teddy Whiley (Corporate Finance) \n\n\n\n\n\n\n\nAlice Lane, Manasa Patil (ECM) \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWG Partners LLP \n\n\n+44 (0) 20 3705 9330\n\n\n\n\nNigel Barnes / Claes Spång \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR \n\n\n+44 (0)20 7933 87870 or [email protected]\n\n\n\n\nPaul McManus / Anna Dunphy \n\n\n+44 (0)7980 541 893 / +44 (0)7876 741 001\n\n\n\n \n \nAbout Evgen Pharma plc \nEvgen Pharma is a clinical stage company developing sulforaphane based medicines for the treatment of multiple diseases The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. \n \nThe Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. Our lead product, SFX-01, has demonstrated efficacy in a Phase II trial for advanced metastatic ...